The study will be conducted in two parts: We hope this study will shed light on both the impact of TD and care strategies that can help improve outcomes for patients, as we know TD can disrupt patients’ underlying mental health treatment plan.” “At Teva, we are deeply committed to improving the lives of patients and families impacted by mental illness and ensuring that scientific innovation is as focused on mental health as it is on physical health. “We are proud to announce the initiation of this important study on TD during Mental Illness Awareness Week – a time dedicated to raising awareness of mental illness and stigma and highlighting the reality of living with a mental health condition,” said Denisa Hurtukova, MD, VP, Head of North America Medical Affairs. In fact, three out of four people who have TD say it severely impacts how they function, feel, and interact with others. 1 Whether symptoms are mild, moderate, or severe, the impact of TD can be significant. In addition, both patient- and clinician-reported outcomes will be captured to help determine the severity and multidimensional impact of TD on patients.”Īn irreversible, chronic condition, TD causes a person to experience sudden, random movements in their face and other body parts. “This study aims to collect data to better understand how TD impacts a person’s daily life and how the condition changes over time. “TD is a chronic, highly debilitating condition that affects one in four people who take certain mental health treatments, yet the long-term impact, burden and treatment patterns in everyday clinical practice are not well understood,” said Richard Jackson, MD, an Assistant Clinical Adjunct Professor in the University of Michigan School of Medicine’s Department of Psychiatry and the study’s lead investigator. The study will evaluate how the condition progresses over time and impacts a person’s quality of life, as well as outcomes related to treatment with AUSTEDO (deutetrabenazine) tablets. The Phase 4, multicenter, prospective, observational two-part study is the largest-ever study of its kind for TD and will collect information from both patients and physicians on TD. (NYSE and TASE: TEVA), today announced the initiation of a 3-year longitudinal registry and study to assess the impact of tardive dyskinesia (TD) and real-world treatment patterns and outcomes. affiliate of Teva Pharmaceutical Industries Ltd. TEL AVIV, Israel & PARSIPPANY, N.J.-( BUSINESS WIRE)-Teva Pharmaceuticals, a U.S.
0 kommentar(er)
